SANGAMO THERAPEUTICS, INC
10-K March 30, 2026
Key Highlights
- Lead drug candidate isaralgagene civaparvovec (ST-920) for Fabry disease has com...
- Active regulatory discussions with the FDA are underway to define the approval p...
- Strategic partnerships with major biotech firms like Pfizer and Genentech provid...
Read Analysis
π€ AI Generated